Effects of dornase alfa: A Synthesis of Findings from 25 Studies

  1. Home
  2. Effects of dornase alfa
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of dornase alfa: A Synthesis of Findings from 25 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of dornase alfa: A Synthesis of Findings from 25 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Dornase alfa is a medication used to treat cystic fibrosis (CF) by breaking down the DNA in thick mucus that builds up in the lungs, making it easier to cough up. 1 This can help improve lung function, reduce airway infections, and potentially prevent lung damage. 1

Studies have shown that dornase alfa may also be effective in treating other conditions, such as clogged ear tubes in children, where DNA buildup is a contributing factor. 3 Additionally, there’s emerging evidence suggesting dornase alfa could play a role in managing acute respiratory distress syndrome (ARDS), particularly in cases triggered by trauma or COVID-19. 24 12 The reasoning behind this is that dornase alfa can break down neutrophil extracellular traps (NETs), which are structures released by immune cells that can contribute to inflammation and lung damage in ARDS. 24

Long-term use of dornase alfa in CF patients has been investigated and found to have no apparent negative impact on lung function. 2 However, further research is needed to confirm this definitively. 2

Benefits and Risks

Benefit Summary

Dornase alfa can be beneficial for CF patients by reducing the thickness and stickiness of mucus, making it easier to cough up. 1 This can lead to improved lung function, reduced frequency of respiratory infections, and potentially better overall lung health. 1

Risk Summary

Potential risks associated with using dornase alfa include worsening of asthma symptoms, throat irritation, coughing, fever, and headache. 1 It’s important to note that these side effects are not common and may not occur in all patients. 1

Comparison Across Studies

Commonalities

Many studies have demonstrated the effectiveness of dornase alfa in reducing mucus viscosity and improving lung function in CF patients. 1 2

Differences

The methods of administration, dosage, and target conditions for dornase alfa vary across studies. 1 2 For example, some studies focus on CF patients, while others explore its potential benefits for other conditions like ARDS. 24

Consistency and Contradictions in Findings

The majority of research consistently supports dornase alfa’s ability to break down mucus and improve lung function in CF. 1 2 However, the long-term effects of dornase alfa use, particularly on lung function and potential side effects, require further investigation. 2

Considerations for Everyday Application

It is crucial to use dornase alfa under the guidance of a healthcare professional. 1 Self-treating with dornase alfa or combining it with other medications without medical supervision is not recommended. 1 Also, keep in mind that dornase alfa may not be effective for all individuals. 1

Current Research Limitations

The long-term effects of dornase alfa use on lung function and potential side effects are not fully understood and require more extensive research. 2

Future Research Directions

Future research should focus on long-term effects of dornase alfa on lung function, particularly in the context of potential side effects. 2 Additionally, studies investigating the combination of dornase alfa with other therapies, particularly for conditions like ARDS, are needed. 24

Conclusion

Dornase alfa has demonstrated effectiveness in reducing mucus thickness and improving lung function in CF patients, as supported by numerous studies. 1 2 However, it’s important to remember that dornase alfa might not benefit everyone, and the long-term consequences of its use are still under investigation. 2 When using dornase alfa, follow your doctor’s instructions and be aware of potential side effects. 1

Literature analysis of 25 papers
Positive Content
24
Neutral Content
0
Negative Content
1
Article Type
5
1
1
2
23
1.

Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index.

Author: TerlizziVito, CastellaniChiara, TaccettiGiovanni, FerrariBeatrice

CF treatment
Sputum clearance

This review focuses on dornase alfa, a medication used to treat lung disease in people with cystic fibrosis. Dornase alfa breaks down DNA in mucus, making it easier to clear from the lungs and reducing the risk of airway infections.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

Investigating the effects of long-term dornase alfa use on lung function using registry data.

Author: NewsomeS J, DanielR M, CarrS B, BiltonD, KeoghR H

Improved lung function

The long-term effects of dornase alfa, a common cystic fibrosis (CF) treatment, on lung function are being investigated using UK CF Registry data.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Dornase Alfa Ototoxic Effects in Animals and Efficacy in the Treatment of Clogged Tympanostomy Tubes in Children: A Preclinical Study and a Randomized Clinical Trial.

Author: ChanKenny H, AllenGregory C, KelleyPeggy E, StreubelSven-Olrik, FriedmanNorman R, YoonPatricia, GaoDexiang, RuizAmanda G, JungTimothy T K

Clogged TT treatment

Dornase alfa is a recombinant molecule that breaks down DNA, making it a potential treatment for clogged tympanostomy tubes (TTs). This is because both middle-ear effusion and the plug are rich in DNA.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.

Author: McCoyK, HamiltonS, JohnsonC

Improved lung function
Death

Aerosolized recombinant human DNase (dornase alfa) improved pulmonary function in patients with cystic fibrosis (CF) with advanced lung disease. The mean percent change in FEV1 was 9.4% in the dornase alfa group compared to 2.1% in the placebo group.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Emulated trial investigating effects of multiple treatments: estimating combined effects of mucoactive nebulisers in cystic fibrosis using registry data.

Author: GrangerEmily, DaviesGwyneth, KeoghRuth H

CF treatment
Lung function improvement

This study investigates whether adding hypertonic saline (HS) to dornase alfa (DNase) therapy provides additional benefits for lung function and antibiotic use in people with cystic fibrosis (CF). The study aims to assess the combined effects of these commonly used mucoactive nebulisers.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Cystic Fibrosis: A Review.

Author: OngThida, RamseyBonnie W

Multiorgan dysfunction
Shortened life expectancy

This abstract describes cystic fibrosis (CF), a genetic disorder caused by variants in the CFTR gene, and its impact on life expectancy.

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Recombinant human DNase-I improves acute respiratory distress syndrome via neutrophil extracellular trap degradation.

Author: JarrahiAbbas, KhodadadiHesam, MooreNicholas S, LuYujiao, AwadMohamed E, SallesEvila L, VaibhavKumar, BabanBabak, DhandapaniKrishnan M

Improved pulmonary perfusion
Reduced inflammation

This study investigated the effects of recombinant human DNase-I (rhDNase) on inflammation, coagulation, and pulmonary perfusion in a mouse model of acute respiratory distress syndrome (ARDS). rhDNase degraded neutrophil extracellular traps (NETs) and attenuated platelet activation, resulting in reduced inflammation, normalized clotting time, and improved pulmonary perfusion. The findings suggest that rhDNase could be a promising therapeutic approach for ARDS.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

9.

Effect of Dornase Alfa on the Lung Clearance Index in Children with Cystic Fibrosis: A Lesson from a Case Series.

Author: TerlizziVito, ParisiGiuseppe Fabio, FerrariBeatrice, CastellaniChiara, MantiSara, LeonardiSalvatore, TaccettiGiovanni

CF treatment

This report highlights the experience of two CF centers using lung clearance index (LCI) monitoring to evaluate the efficacy of dornase alfa (DNase) therapy in cystic fibrosis (CF) patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

10.

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.

Author: Mayer-HamblettNicole, RatjenFelix, RussellRenee, DonaldsonScott H, RiekertKristin A, SawickiGregory S, Odem-DavisKatherine, YoungJulia K, RosenbluthDaniel, Taylor-CousarJennifer L, GossChristopher H, Retsch-BogartGeorge, ClancyJohn Paul, GenatossioAlan, O'SullivanBrian P, BerlinskiAriel, MillardSusan L, OmlorGregory, WyattColby A, MoffettKathryn, NicholsDavid P, GiffordAlex H,

Reduced treatment burden

The SIMPLIFY study aimed to assess the effects of discontinuing nebulized hypertonic saline or dornase alfa in cystic fibrosis patients using the CFTR modulator elexacaftor plus tezacaftor plus ivacaftor (ETI). This study aimed to reduce treatment burden for cystic fibrosis patients.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Modified regimen intrapleural alteplase with pulmozyme in pleural infection management: a tertiary teaching hospital experience.

Author: CheongXiong Khee, BanAndrea Yu-Lin, NgBoon Hau, Nik AbeedNik Nuratiqah, Nik IsmailNik Azuan, Nik FuadNik Farhan, Syed ZakariaSyed Zulkifli, GhanSheah Lin, Abdul HamidMohamed Faisal

Complex effusion treatment
IPFT efficacy

This study aimed to assess the effectiveness and safety of a modified intrapleural fibrinolysis therapy (IPFT) regimen for complex pleural infection. The modified regimen involved administering 16mg of alteplase (t-PA) with 5mg of DNase over 24 hours, compared to the previous regimen of 10mg t-PA with 5mg DNase twice daily for 72 hours. The study explores a potentially more efficient and effective treatment approach for complex pleural effusions.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

12.

Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19.

Author: HollidayZachary M, EarhartAlexander P, AlnijoumiMohammed M, KrvavacArmin, AllenLee-Ann H, SchrumAdam G

ARDS treatment

This pilot study evaluated the effects of dornase alfa in patients with Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19. Dornase alfa is a recombinant human deoxyribonuclease I that acts as a mucolytic by cleaving and degrading extracellular DNA.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis.

Author: Ademhan TuralDilber, YalçınEbru, EmiraliogluNagehan, OzsezenBeste, SunmanBirce, Nayir BuyuksahinHalime, GuzelkasIsmail, DogruDeniz, OzcelikUgur, KiperNural

Improved secretion clearance

Inhaled dornase alfa and mannitol are used for improving mucus clearance in cystic fibrosis (CF) patients. This study investigated the long-term effects of adding dry powder inhaled mannitol to daily dornase alfa in CF patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

14.

A Quality Improvement Approach to Influence Value-based Mucolytic Use in the PICU.

Author: GillisHolly Catherine, DolanKevin, SargelCheryl L, ThompsonR Zachary, LutmerJeffrey E

Reduced dornase alfa utilization
Reduced mucolytic cost

A value-based clinical pathway prioritizing pharmacoeconomics in a pediatric intensive care unit significantly reduced dornase-alfa utilization, resulting in sustained mucolytic cost reduction. The pathway did not adversely affect patient outcomes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

Proteome Profiling of Recombinant DNase Therapy in Reducing NETs and Aiding Recovery in COVID-19 Patients.

Author: FisherJane, MohantyTirthankar, KarlssonChristofer A Q, KhademiS M Hossein, MalmströmErik, FrigyesiAttila, NordenfeltPontus, MalmstromJohan, LinderAdam

COVID-19 Treatment
Pulmozyme

This study shows that high levels of neutrophil extracellular traps (NETs) are present in sputum from patients with severe COVID-19, contributing to acute respiratory failure. Treatment with aerosolized Pulmozyme, a recombinant human DNase, improved oxygen saturation and recovery in patients, suggesting that targeting NETs could be a therapeutic strategy for COVID-19.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Dornase alfa for cystic fibrosis.

Author: YangConnie, MontgomeryMark

Dornase alfa
Lung function
Cystic fibrosis
Pulmonary disease
Rash
Voice alteration

Dornase alfa, a mucolytic drug, may improve lung function in people with cystic fibrosis. It is probably associated with a decrease in pulmonary exacerbations in trials of 6 months or longer. The most common adverse events reported were voice alteration and rash. More research is needed to determine if dornase alfa is superior to other hyperosmolar agents.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

17.

Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis.

Author: VoldbyChristian, GreenKent, PhilipsenLue, SandvikRikke Mulvad, SkovMarianne, BuchvaldFrederik, PresslerTacjana, NielsenKim Gjerum

CF lung disease treatment

The lung clearance index (LCI) is an outcome measure in clinical trials of patients with mild cystic fibrosis. This study assessed the impact of withdrawing nebulized dornase alfa on LCI in school-age children with cystic fibrosis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design.

Author: Mayer-HamblettNicole, NicholsDavid P, Odem-DavisKatherine, RiekertKristin A, SawickiGreg S, DonaldsonScott H, RatjenFelix, KonstanMichael W, SimonNoah, RosenbluthDaniel B, Retsch-BogartGeorge, ClancyJohn P, VanDalfsenJill M, BuckinghamRachael, GiffordAlex H

Cystic fibrosis treatment

This study describes SIMPLIFY, a master protocol for evaluating the impact of discontinuing hypertonic saline or dornase alfa in people with cystic fibrosis (CF) who are stable on elexacaftor/tezacaftor/ivacaftor (ETI) therapy. The study aims to assess whether these therapies can be safely discontinued without compromising clinical benefit.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Cryptococcal empyema treated with tube thoracostomy and intrapleural fibrinolysis.

Author: KohliAkshay, SachdevaAshutosh, PickeringEdward M

Empyema treatment
Fibrinolysis
Cryptococcal infection
Immunodeficiency

This case report describes a successful treatment of cryptococcal empyema with tube thoracostomy and intrapleural fibrinolysis, an alternative to surgical drainage in high-risk patients.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

21.

Efficacy and safety of aerosolized intra-tracheal dornase alfa administration in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS): a structured summary of a study protocol for a randomised controlled trial.

Author: DesillesJ P, GregoireC, Le CossecC, LambertJ, MophaweO, LosserM R, LambiotteF, Le TaconS, CantierM, EngrandN, TrouillerP, PottecherJ

ARDS treatment

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause severe pneumonia in COVID-19 patients through the release of damage-associated molecular patterns (DAMPs) and neutrophil recruitment. Activated neutrophils release neutrophil extracellular traps (NETs), contributing to inflammation and alveolar injury. This study discusses the potential benefits of dornase alfa, a recombinant human DNAse 1, in treating COVID-19 patients with acute respiratory distress syndrome (ARDS) by breaking up cell-free DNA, loosening mucus, and reducing NETs-induced toxicity on alveolar pneumocytes.

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
LetterA written message for communication and exchange of information between individuals.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

23.

Human Deoxyribonuclease (rhDNase) Nebulization as an Alternative Treatment for Refractory Plastic Bronchitis After Fontan Surgery.

Author: GrazioliSerge, RougemontAnne-Laure, Ruchonnet-MétraillerIsabelle

Plastic bronchitis treatment
rhDNAse therapy

This case report describes a 5-year-old boy with chronic plastic bronchitis following Fontan surgery. The patient experienced an acute exacerbation and was successfully treated with inhaled rhDNAse due to the bleeding risk associated with inhaled fibrinolytics. The case highlights the use of rhDNAse as a safe and effective alternative in patients on anticoagulants.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

24.

Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients.

Author: PottecherJulien, NollEric, BorelMarie, AudibertGérard, GetteSébastien, MeyerChristian, GaertnerElisabeth, LegrosVincent, CarapitoRaphaël, Uring-LambertBéatrice, SauleauErik, LandWalter G, BahramSeiamak, MeyerAlain, GenyBernard, DiemunschPierre

Trauma-induced lung injury treatment

Dornase alfa, a recombinant DNase, may be beneficial for treating acute respiratory distress syndrome (ARDS) after severe trauma. It works by breaking down extracellular DNA, which is a component of neutrophil extracellular traps (NETs) and damage-associated molecular patterns (DAMPs) that contribute to ARDS. Experimental studies have shown that aerosolized dornase alfa can reduce trauma-induced lung injury and improve oxygenation in ventilated patients.

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

25.

In vitro effects of combined iron chelation, antibiotics and matrix disruption on clinical isolates of Pseudomonas aeruginosa.

Author: NairArun, PerryAudrey, PerryJohn D, GouldF Kate, SamuelJulie

Improved airway efficacy

This study evaluated the effectiveness of desferrioxamine, Dornase alfa (DNase), and antibiotics in disrupting and preventing biofilm formation by Pseudomonas aeruginosa, a common pathogen in respiratory diseases.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.